Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Antiviral Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DDX3X drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DDX3X Recombinant Protein (WT & Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active site configurations. |
View DDX3X Products |
| Gene Delivery | DDX3X Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for target engagement and rescue assays. |
View DDX3X Products |
| Benchmark Ab | Anti-DDX3X Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View DDX3X Products |
| Validator | DDX3X siRNA Set For knockdown verification and functional rescue assays. |
View DDX3X Products |
| Related Target A | DDX5 Closely related DEAD-box helicase family member. Essential for off-target selectivity screening. |
View DDX5 Products |
| Related Target B | eIF4A1 Translational initiation helicase. Synergistic target in oncogenic translation inhibition. |
View eIF4A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity over DDX5/DDX1 helicases | Highly purified DDX5 and related DEAD-box ortholog proteins available (>95% purity) for counter-screening |
| Mutant-specific drug resistance profiling | Recombinant DDX3X mutant panels (e.g., cancer-associated mutations) strictly verified by mass spec |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control expression vectors included |
| False Positives in Enzymatic Assays | Validated siRNA included for orthogonal biological specificity checks |
Live DDX3/DDX3X R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of DDX3 (specifically the X-linked isoform DDX3X) is rapidly gaining momentum. As an ATP-dependent RNA helicase, DDX3X is a critical node regulating translation initiation, RNA splicing, and nuclear export. It is highly overexpressed in aggressive malignancies (such as medulloblastoma, colorectal cancer, AML, and breast cancer) and serves as an essential host factor for viral replication (including HIV-1, HCV, Dengue, and SARS-CoV-2).
The race for DDX3X therapeutics is intensifying, with major players shifting focus from non-specific RNA-binding inhibitors to highly selective ATP-binding pocket inhibitors and PROTAC degraders. As first-generation small molecules reach clinical and preclinical validation, the next wave of R&D is targeting mutant-specific forms of DDX3X to overcome systemic toxicity and drug resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | First Wave BioPharma, Academic Spin-offs | Solid Tumors (Medulloblastoma, Colorectal), Viral Infections | Enzymatic ATPase & Helicase Assays (Requires highly active, sequence-verified WT protein) |
| PROTAC Degraders | Oncology-focused Biotechs | Hematological Malignancies (AML, Lymphoma) | Target Engagement & Cellular Ubiquitination (Requires Lentivirus for stable reporter cell lines) |
| Combination Therapies | Clinical Research Consortiums | Drug-resistant Cancers, Antiviral Cocktails | Selectivity Counter-screening (Requires DDX5/eIF4A1 panels to rule out pan-helicase toxicity) |